Grant: Doctoral Research Award: Canada Graduate Scholarships
McMaster University
$105,000.00
Investigating the role of dietary tryptophan metabolism by intestinal microbiota in inflammatory bowel disease
FY 2020-21
Summary
Our gut is exposed to a vast number of bacteria and microorganisms, called microbiota, which in combination with food, are important for maintaining good health. There is growing evidence suggesting that when food-bacterial interactions are broken, conditions like inflammatory bowel disease (IBD) can develop. IBD is a chronic relapsing disease that is increasing in prevalence worldwide, has no cure, and is characterized by severe inflammation in the digestive tract. I propose to study how certain bacteria from the human gut metabolize dietary proteins like tryptophan, to produce molecules which activate a receptor called the (A)ryl (H)ydrocarbon (R)eceptor (AhR). Recent studies have shown that AhR function is abnormal in patients with IBD. This is likely explained by changes in gut microbiota, resulting in a decrease of molecules which activate AhR ("agonists"). What is not known is which bacteria are responsible for the defective production of AhR agonists from foods, and the metabolic pathways involved. In this project I will study and isolate bacteria involved in tryptophan metabolism from IBD patients and healthy people. I will assess their ability to metabolize tryptophan and create AhR agonists using germ-free mice colonized with the selected bacteria. Finally, I will use models of colitis to study the ability of these bacteria to restore AhR function and decrease inflammation and injury in models of colitis. About 1% of the Canadian population could be affected by IBD by 2030. Additionally, current therapies to induce and maintain remission are dominated by drugs that lose effectiveness over time. This suggests the need for complementary therapies. My long-term goal is to develop combinations of bacteria or probiotics, which act on tryptophan in foods to restore AhR function and prevent and treat IBD.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
439570
Name
Rondeau Liam E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the role of dietary tryptophan metabolism by intestinal microbiota in inflammatory bowel disease
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Diet; Inflammation; Inflammatory Bowel Disease; Microbiota; Nutrition; Probiotic
Abstract
Our gut is exposed to a vast number of bacteria and microorganisms, called microbiota, which in combination with food, are important for maintaining good health. There is growing evidence suggesting that when food-bacterial interactions are broken, conditions like inflammatory bowel disease (IBD) can develop. IBD is a chronic relapsing disease that is increasing in prevalence worldwide, has no cure, and is characterized by severe inflammation in the digestive tract. I propose to study how certain bacteria from the human gut metabolize dietary proteins like tryptophan, to produce molecules which activate a receptor called the (A)ryl (H)ydrocarbon (R)eceptor (AhR). Recent studies have shown that AhR function is abnormal in patients with IBD. This is likely explained by changes in gut microbiota, resulting in a decrease of molecules which activate AhR ("agonists"). What is not known is which bacteria are responsible for the defective production of AhR agonists from foods, and the metabolic pathways involved. In this project I will study and isolate bacteria involved in tryptophan metabolism from IBD patients and healthy people. I will assess their ability to metabolize tryptophan and create AhR agonists using germ-free mice colonized with the selected bacteria. Finally, I will use models of colitis to study the ability of these bacteria to restore AhR function and decrease inflammation and injury in models of colitis. About 1% of the Canadian population could be affected by IBD by 2030. Additionally, current therapies to induce and maintain remission are dominated by drugs that lose effectiveness over time. This suggests the need for complementary therapies. My long-term goal is to develop combinations of bacteria or probiotics, which act on tryptophan in foods to restore AhR function and prevent and treat IBD.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rondeau, Liam E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~